Cargando…

Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR

We report the case of a tertiary cytoreductive surgery for isolated lymph-node recurrence (ILNR) in a 54-years old Brest cancer 2 (BRCA 2) mutated patients, with a personal history of ovarian cancer previously treated elsewhere. She was admitted to our department for a suspected isolated lymph-nodal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Matteo, Ludovisi, Manuela, Ronsini, Carlo, Capanna, Giulia, Stabile, Guglielmo, Guido, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056081/
https://www.ncbi.nlm.nih.gov/pubmed/36984607
http://dx.doi.org/10.3390/medicina59030606
_version_ 1785016038531792896
author Bruno, Matteo
Ludovisi, Manuela
Ronsini, Carlo
Capanna, Giulia
Stabile, Guglielmo
Guido, Maurizio
author_facet Bruno, Matteo
Ludovisi, Manuela
Ronsini, Carlo
Capanna, Giulia
Stabile, Guglielmo
Guido, Maurizio
author_sort Bruno, Matteo
collection PubMed
description We report the case of a tertiary cytoreductive surgery for isolated lymph-node recurrence (ILNR) in a 54-years old Brest cancer 2 (BRCA 2) mutated patients, with a personal history of ovarian cancer previously treated elsewhere. She was admitted to our department for a suspected isolated lymph-nodal pelvic recurrence. A positron emission tomography acquisition with contrast enhanced computed tomography (PET-CT) scan revealed an increased node at the level of the right external iliac (SUV 6.9) in correspondence with the obturator nerve, which was confirmed by transvaginal ultrasound. Since the recurrence was in a single site and the patient had previously undergone three lines of chemotherapy and maintenance with Poly(ADP-ribose) polymerase (PARP) inhibitors, we decided to perform tertiary cytoreductive surgery by minimally invasive laparoscopic approach. After gradual and careful isolation of the obturator nerve, lumbo-sacral trunk and venous vessels afferent to the external and internal iliac vein, the suspected node has been removed. No intra- and postoperative complications occurred. The patient was discharged three days after procedure. We decided to quarterly follow-up; actually, after 16 months no recurrence was detected. Several studies have reported ILNR as a unique clinical disease with low growth rate and less chemosensitivity; this can lead to considered ILNR more susceptible to take advantage of surgical treatment, even in case of second or third recurrence. The BRCA mutational status seems to play a role in the decision-making process in the approach to patients with platinum sensitive relapse of ovarian cancer or in specific isolated forms of recurrence such as the hepatic one. However, data on frequency and prognostic impact of BRCA gene mutation in ILNR are very limited. In this article we investigated the role of BRCA 1 or 2 mutational status in this rare pattern of recurrence according to more recent advances in literature.
format Online
Article
Text
id pubmed-10056081
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100560812023-03-30 Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR Bruno, Matteo Ludovisi, Manuela Ronsini, Carlo Capanna, Giulia Stabile, Guglielmo Guido, Maurizio Medicina (Kaunas) Case Report We report the case of a tertiary cytoreductive surgery for isolated lymph-node recurrence (ILNR) in a 54-years old Brest cancer 2 (BRCA 2) mutated patients, with a personal history of ovarian cancer previously treated elsewhere. She was admitted to our department for a suspected isolated lymph-nodal pelvic recurrence. A positron emission tomography acquisition with contrast enhanced computed tomography (PET-CT) scan revealed an increased node at the level of the right external iliac (SUV 6.9) in correspondence with the obturator nerve, which was confirmed by transvaginal ultrasound. Since the recurrence was in a single site and the patient had previously undergone three lines of chemotherapy and maintenance with Poly(ADP-ribose) polymerase (PARP) inhibitors, we decided to perform tertiary cytoreductive surgery by minimally invasive laparoscopic approach. After gradual and careful isolation of the obturator nerve, lumbo-sacral trunk and venous vessels afferent to the external and internal iliac vein, the suspected node has been removed. No intra- and postoperative complications occurred. The patient was discharged three days after procedure. We decided to quarterly follow-up; actually, after 16 months no recurrence was detected. Several studies have reported ILNR as a unique clinical disease with low growth rate and less chemosensitivity; this can lead to considered ILNR more susceptible to take advantage of surgical treatment, even in case of second or third recurrence. The BRCA mutational status seems to play a role in the decision-making process in the approach to patients with platinum sensitive relapse of ovarian cancer or in specific isolated forms of recurrence such as the hepatic one. However, data on frequency and prognostic impact of BRCA gene mutation in ILNR are very limited. In this article we investigated the role of BRCA 1 or 2 mutational status in this rare pattern of recurrence according to more recent advances in literature. MDPI 2023-03-19 /pmc/articles/PMC10056081/ /pubmed/36984607 http://dx.doi.org/10.3390/medicina59030606 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Bruno, Matteo
Ludovisi, Manuela
Ronsini, Carlo
Capanna, Giulia
Stabile, Guglielmo
Guido, Maurizio
Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR
title Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR
title_full Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR
title_fullStr Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR
title_full_unstemmed Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR
title_short Tertiary Cytoreduction for Isolated Lymphnode Recurrence (ILNR) Ovarian Cancer in a BRCA2 Mutated Patient: Our Experience and Prevalence of BRCA 1 or 2 Genes Mutational Status in ILNR
title_sort tertiary cytoreduction for isolated lymphnode recurrence (ilnr) ovarian cancer in a brca2 mutated patient: our experience and prevalence of brca 1 or 2 genes mutational status in ilnr
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10056081/
https://www.ncbi.nlm.nih.gov/pubmed/36984607
http://dx.doi.org/10.3390/medicina59030606
work_keys_str_mv AT brunomatteo tertiarycytoreductionforisolatedlymphnoderecurrenceilnrovariancancerinabrca2mutatedpatientourexperienceandprevalenceofbrca1or2genesmutationalstatusinilnr
AT ludovisimanuela tertiarycytoreductionforisolatedlymphnoderecurrenceilnrovariancancerinabrca2mutatedpatientourexperienceandprevalenceofbrca1or2genesmutationalstatusinilnr
AT ronsinicarlo tertiarycytoreductionforisolatedlymphnoderecurrenceilnrovariancancerinabrca2mutatedpatientourexperienceandprevalenceofbrca1or2genesmutationalstatusinilnr
AT capannagiulia tertiarycytoreductionforisolatedlymphnoderecurrenceilnrovariancancerinabrca2mutatedpatientourexperienceandprevalenceofbrca1or2genesmutationalstatusinilnr
AT stabileguglielmo tertiarycytoreductionforisolatedlymphnoderecurrenceilnrovariancancerinabrca2mutatedpatientourexperienceandprevalenceofbrca1or2genesmutationalstatusinilnr
AT guidomaurizio tertiarycytoreductionforisolatedlymphnoderecurrenceilnrovariancancerinabrca2mutatedpatientourexperienceandprevalenceofbrca1or2genesmutationalstatusinilnr